Dr. Bellmunt returns to Barcelona after almost 4 years in the US heading up the bladder cancer unit in one of America's top cancer hospitals, and an international benchmark in cancer treatment, the Dana Farber Cancer Institute.
Joaquim Bellmunt Molins, a genitourinary cancer specialist and a world leader in bladder and kidney cancer, has been selected to be Director of Research at the Parc de Salut Mar (PSMAR) in Barcelona and director of the Hospital del Mar Medical Research Institute (IMIM). Putting a professional with both clinical and management experience at an international level at the head of the PSMAR's research and as director of the IMIM will help research strategies align with healthcare goals and increasingly position the institution as global leader in research applied to patients. His incorporation will be effective as of November 14.
Dr. Bellmunt was the head of the Solid Tumours section at Hospital del Mar from 2006 to 2013, leading the clinical research into genitourinary cancer at the IMIM. In March 2013, he was given the job of directing the Bladder Cancer Centre, a consortium comprising the Dana Farber Cancer Institute in Boston, one of the best cancer centres in the world, and the Brighman and Women's Hospital. During his time in the US, he was appointed associate professor of medicine at Harvard University, a position he kept until his transition to our university. During this time, he maintained his links with the IMIM and PSMAR.
He is a co-founder of the Spanish Group of Genitourinary Tumour Treatment and an advisor to the world's most prestigious publications in his speciality. He has authored more than 275 refereed articles and over 300 conference papers and book chapters. He is also a member of the American Society for Cancer Research and the American Association of Medical Oncology as well as being part of the scientific committee of the American Society of Clinical Genitourinary Oncology. In Catalonia, he is an expert consultant in the design and development of the "Oncoguides" for CatSalut.
His most important recent contribution was leading the international phase III study that revealed positive survival results for treatment with Pembrolizumab (immunotherapy) in advanced bladder cancer.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
